Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors

Dig Liver Dis. 2021 Dec;53(12):1664-1665. doi: 10.1016/j.dld.2021.09.001. Epub 2021 Oct 20.

Authors

Marine Valery¹, Francesco Facchinetti², David Malka³, Michel Ducreux³, Luc Friboulet², Antoine Hollebecque⁴

Affiliations

¹ Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France. Electronic address: [email protected].
² Research Team in Molecular Biology, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
³ Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
⁴ Research Team in Molecular Biology, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France; Department of Therapeutic Innovation and Early Trials, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.

PMID: 34556462
DOI: 10.1016/j.dld.2021.09.001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aminopyridines / administration & dosage*
Anaplastic Lymphoma Kinase
Bile Duct Neoplasms / drug therapy*
Bile Duct Neoplasms / genetics
Calmodulin-Binding Proteins
Cholangiocarcinoma / drug therapy*
Cholangiocarcinoma / genetics
Female
Humans
Lactams / administration & dosage*
Membrane Proteins
Nerve Tissue Proteins
Pyrazoles / administration & dosage*
Receptor Protein-Tyrosine Kinases / genetics
Translocation, Genetic / genetics

Substances

Aminopyridines
Calmodulin-Binding Proteins
Lactams
Membrane Proteins
Nerve Tissue Proteins
Pyrazoles
STRN protein, human
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases
lorlatinib